Seven-Year Clinical Outcomes of a Magnesium Bioresorbable Scaffold in Acute Coronary Syndrome: A Door Opened for the Next Generation.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as an observational study.

To evaluate 7-year clinical outcomes in ACS patients treated with MgBRS, and to compare event rates between early (24 ± 7 months) and late (6.7 ± 0.6 years) follow-up periods.

Why It Was Studied

Magnesium-based bioresorbable scaffolds (MgBRS) offer theoretical advantages over permanent metallic stents in percutaneous coronary intervention, particularly for younger patients or those with vulnerable plaques in acute coronary syndrome (ACS).

However, early clinical outcomes with MgBRS have been inconsistent, and long-term data remain scarce.

Who Took Part

The abstract describes 90 patients taking part.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

This prospective, multicenter, observational study included 90 ACS patients treated with MgBRS between 2016 and 2018.

All patients completed long-term clinical follow-up.

How the Study Was Run

The researchers set it up as a multicenter study.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

Secondary endpoints included each individual component of the DOCE and scaffold thrombosis (ST).

What Was Measured

However, early clinical outcomes with MgBRS have been inconsistent, and long-term data remain scarce.

PubMed files the paper under topics including Absorbable Implants, Magnesium, Acute Coronary Syndrome, Prosthesis Design, Percutaneous Coronary Intervention, Risk Factors and Risk Assessment.

The authors tagged it with the keywords long‐term outcomes and magnesium bioresorbable scaffold.

What This Means in Plain Language

The paper is a multicenter study of Vitamin D, K2, Magnesium and Zinc in 90 patients.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.